Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.36 |
| ▸ | PGR | P06401 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23479213 | 0.85 | PDE10A (0.46) | NR3C1NR3C2PGR | |
| SCHEMBL23479351 | 0.83 | SCN10A (0.40) | CYP3A4POLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23453154 | 0.73 | DAO (0.42) | CYP3A4NR3C1NR3C2PGR | |
| SCHEMBL868184 | 0.72 | DDAH1 (0.59) | RAD52UBE2NCYP3A4POLBCYP1A2 | |
| SCHEMBL12571647 | 0.69 | DAO (0.49) | CYP3A4NR3C1NR3C2PGRNPC1 | |
| SCHEMBL8596529 | 0.68 | KDM4E (0.55) | RAD52UBE2NCYP3A4POLBCYP1A2 | |
| SCHEMBL15947594 | 0.68 | TDP1 (0.61) | RAD52UBE2NCYP3A4POLBCYP1A2 | |
| SCHEMBL20993310 | 0.68 | NR3C1 (0.38) | CYP3A4NR3C1NR3C2PGR | |
| SCHEMBL23840768 | 0.66 | DAO (0.46) | CYP3A4NR3C1NR3C2PGR | |
| SCHEMBL12092412 | 0.66 | DDAH1 (0.59) | NPC1RAB9APKMSMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | RAD52 953/4885UBE2N 1778/4885CYP3A4 4706/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | RAD52 953/4885UBE2N 1778/4885CYP3A4 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.